which may represent a better measure of physiologic complement activity and perhaps more indicative of complement-mediated injury in the graft. In this study, our objectives were to (1) determine the utility of C3d to predict graft loss in a multicenter cohort of kidney recipients presenting with late clinical dysfunction; and (2) assess the prognostic value of C3d after accounting for antibody strength as measured in MFI values.
| MATERIAL S AND ME THODS

| Patient population
DeKAF is a multicenter consortium of 7 US-Canadian centers aimed at correlating specific clinico-pathologic entities with allograft dysfunction. 19 Patients in the prospective arm (n = 1948) were enrolled at the time of kidney transplantation-they were required to have a stable baseline renal function (average of 3 serum creatinine values) at 3 months posttransplant. Patients in the cross-sectional cohort (n = 559) received a transplant prior to October 1, 2005 and had a serum creatinine level ≤ 2 mg/dL prior to study entry. All subjects were followed longitudinally for development of graft dysfunction, defined as a ≥ 25% increase in serum creatinine or new-onset proteinuria, which then triggered an allograft biopsy and concurrent serum testing for DSA by a central laboratory (UCLA Immunogenetics). 19 Biopsies were read both locally and by a blinded central pathologist (Mayo Clinic, Rochester, MN). IgG platform (n = 3), graft failure < 7 days from time of dysfunction (n = 7), and patient exposure to antibody-depleting therapy prior to serum collection for DSA testing (n = 13), leaving 106 patients for analysis. This study was approved by the institutional review board at UCLA (IRB 11-000456).
| Anti-HLA antibody testing
Donor-recipient HLA typing was performed at each of the participating DeKAF centers' HLA laboratories using their existing protocols. Given the era of transplants, typing for HLA-Cw, -DQA, and -DPA/B was generally unavailable. Assignment of donor reactivity in HLA-Cw and -DQA loci was based on strong linkage disequilibrium;
DSA to DP antigens could not be determined. Overall, 4.7% (5/106) of the study recipients had evidence of anti-DP antibodies.
Patient sera stored at the time of kidney biopsy were retested using Immucor LSA Class I and II Single Antigens (Lot 04234B, Immucor Transplant Diagnostics, Inc., Stamford, CT) by an experienced technologist (George Benzuela) at the UCLA Immunogenetics
Laboratory. Antibody specificities with MFI ≥ 500 were defined as positive. The same serum samples were reanalyzed using the Immucor LSA C3d assay (Lot 04234B) according to manufacturer's instructions. Antibody reactivities were adjusted for background by subtracting the MFI value of beads in patient wells from those derived from the negative control well. A threshold of MFI ≥ 500 was used to define C3d positivity. Whenever multiple donor-specific reactivities were present in the same serum, peak DSA referred to the antibody specificity exhibiting the highest MFI value relative to the others present. Relationships between antibody strength and C3d positivity were derived using Immucor MFI values. 
| Statistical analysis
Graft survival rates were defined as time from biopsy to return to dialysis. Survival functions, censoring for death, were calculated using the Kaplan-Meier method and compared with the Wilcoxon test.
Categorical variables were compared using Fisher's exact test; data for race were compared using the chi-square test. Continuous variables were expressed as mean ± SD and analyzed using Student's t test. Predictors of graft loss were evaluated using univariate and multivariate Cox proportional hazards models. Variables with P < .1
were selected to construct the multivariate model. All comparisons were 2 sided, and P < .05 were considered to be statistically significant. STATA version 13, R version 3.4.3, and GraphPad version 7.0d
were used for statistical analysis.
| RE SULTS
| Baseline patient and anti-HLA antibody characteristics
The study cohort was primarily Caucasian (65.1%), with a significant proportion composed of African-Americans (23.6%). The majority of patients (71.7%) belonged to the cross-sectional cohort. The average time to graft dysfunction was 5.3 ± 5.0 years. (Figure 2A) . Area under the receiver operating curve between the peak DSA MFI and C3d status was 0.919 ( Figure 2B ). A similar correlation was observed by analyzing the sum DSA MFI in relation to C3d status ( Figure 2C,D) . Interestingly, almost all patients (98.3%, n = 57/58) with peak DSA MFI > 10 000 elicited C3d positivity; thus, C3d offered little discriminatory value for strong antibodies defined using this threshold.
| Relationship between C3d positivity and intragraft C4d staining
The correlation between C3d positivity and intragraft C4d was analyzed in 101 biopsy specimens with available C4d staining. As expected, the majority of C3d+ DSA (73%, n = 56/77) were correlated with peritubular C4d deposition in the tissue ( Figure 3A) . 
| Performance of the C3d test and its association with graft survival
Compared with the historical control of DSA-patients in DeKAF (n = 536, baseline clinico-pathologic data in Table S1 ), recipients in this study had a significantly worse posttransplant graft survival rate of 42% at 5 years postbiopsy versus 78% in DSA-recipients ( Figure 4A ). The C3d test further separated the graft outcome of DSA+ patients, with those screening positive for C3d exhibiting inferior graft survival ( Figure 4B ). The rate of graft loss among C3d+ patients was fastest early after biopsy; in contrast, allograft failure in C3d-patients all occurred at least 1 year after clinical dysfunction.
Comparison of DSA characteristics between patients with graft failure versus those with a functioning allograft at 5 years postbiopsy showed no significant differences with respect to DSA class, number, peak and sum IgG DSA MFI, and C3d peak and sum MFI (Table S2 ).
The diagnostic performance of C3d and intragraft C4d in predicting graft loss is shown in Table 2 . Both tests yielded reasonable sensitivity and negative predictive value, particularly when predicting outcome within the first year after biopsy. C3d offered superior sensitivity compared to C4d at all time points analyzed, although a decrease in assay performance was observed when predicting graft survival distant to the test. Complement activation as evaluated by both tests showed poor specificity and positive predictive value for graft survival.
Given the strong dependency of complement activation on antibody strength, we next analyzed a subset of recipients with peak DSA MFI < 10 000 (box in Figure 5A ). Despite exclusion of patients with the strongest antibody reactivities (MFI > 10 000), the inferior graft outcome associated with C3d positivity remained unchanged TA B L E 1 Baseline demographic, clinico-pathologic data, and DSA characteristics of study patients by C3d status To ensure prozone was not a confounder in the interpretation of graft survival data, we performed serial dilution of sera from C3+ patients involved in the subanalysis (shaded box in Figure 5A ). At 1:4 dilution all sera exhibited the expected decrease in MFI values, with the exception of 1 specimen that showed the decrease at 1:16 dilution ( Figure 5C ). Thus, we concluded that complement interference did not have a significant effect in the graft survival comparison. We also analyzed the graft survival of recipient subsets using different peak IgG MFI (< 7000 and < 5000) and sum MFI (< 20 000
and < 10 000) cut-offs. The inferior outcome associated with C3d positivity was consistent under these different conditions ( Figure 6 ).
| Univariate and multivariate models
In a univariate Cox proportional hazards model, significant predictors for death-censored graft loss at 5 years postbiopsy included race, creatinine and proteinuria at time of biopsy, biopsy IFTA, and
C3d positivity (Table 3) . We next sought to determine whether C3d could provide independent prognostic value beyond standard clinico-pathologic data. In a multivariate Cox model, only biopsy IFTA emerged as a significant predictor of graft loss (HR 1.84; 95% CI 1.04-3.26, P = .035). A cross-tabulation between C3d and IFTA showed that the 2 variables were correlated (P = .04), but in terms of risk prediction the value of C3d was usurped after integration with histology.
| D ISCUSS I ON
In this multicenter observational cohort study, the major findings are that patients with circulating C3d+ DSA had a worse renal function and more established graft fibrosis at the time of dysfunction.
These patients developed a rapid rate of graft loss within the first year after dysfunction, leading to an inferior long-term graft survival compared with patients who produced non-complement-fixing DSA.
Notwithstanding the prognostic value of C3d as a stand-alone test, in a multivariate model the amount of fibrosis was the dominant predictor of graft loss, indicating a limited role of the assay when biopsy data are already available.
Previous studies examining the utility of complementdependent assays in kidney transplant patients have yielded mixed TA B L E 2 Performance of the C3d assay and intragraft C4d detection in predicting graft loss at 1, 2, and 3 y post allograft dysfunction results. 4, 6, 9, [12] [13] [14] [15] 21 In a large population-based study, Loupy et al found C1q binding DSA within the first year posttransplant to be associated with a higher degree of graft injury on histopathology and a significantly higher risk of graft failure on follow-up. 4 More recently, both Sicard and Comoli et al found a C3d assay to be more predictive of graft loss compared to C1q. 6, 8 In the cross-sectional screening of a stable cohort of kidney recipients, however, Eskandary et al found complement assays (C1q, C3d, C4d) failed to add additional diagnostic value over standard IgG MFI in the prediction for AMR, although graft outcome was not directly examined in this study. 7 In contrast to Loupy's cohort, patients with C3d+ DSA in this study did not exhibit more active microcirculatory inflammation (g + ptc) on biopsy but rather showed a higher degree of chronic graft fibrosis (ci + ct). Immucor SAB across the MFI continuum, relationships defined between C3d and MFI strength in this study should be viewed as assay specific until confirmatory data are available on the OL platform.
It is intriguing that although a positive C3d signal was found to be closely associated with IgG MFI, the assay was able to further discriminate the pathogenicity of a proportion of low-moderate strength antibodies, where factors other than antibody strength produced a positive signal on the test. In previous experimental work, synergy between polyspecific antibodies binding in close proximity to distinct epitopes on the same HLA molecule was a major determinant of in vivo complement activation. 27, 28 Whether a similar mechanism occurs in vitro on antigen-coated beads remains to be elucidated. In a related finding, 29% of patients of C3d-DSA had detectable intragraft C4d. Although issues with assay sensitivity and/or alternative complement pathway activation in the graft could account for this discordance, we found a higher proportion of Although we found C3d to be prognostic of graft failure as a stand-alone test along the continuum of MFI values, we did not confirm the independent predictive value of C3d as demonstrated in a previous publication. 6 In 2 recent studies that evaluated C3d in kidney recipients, one did not directly examine graft failure as the primary outcome, and the other did not include histology in the risk prediction model. 7, 8 Although C3d positivity and graft fibrosis were found to be correlated in our analysis, in a combined model graft fibrosis was a better predictor of graft loss, lending further support to the value of histology both in the diagnosis of AMR and prognosis of TA B L E 3 Univariate and multivariate models of risk factors for death-censored graft survival at 5 y post dysfunction Variables with P < .10 in the univariate analysis were selected to construct the multivariate model. outcome. 7, 15 Despite this limitation, the C3d test may be considered in cases where a kidney biopsy is not permitted or in patients where longitudinal risk stratification is desired after an incident biopsy. In these scenarios, both our data and others 15 showed that a sensitivity and specific threshold for predicting in vitro complement activity is achievable; thus, the assay is most efficient in the risk discrimination of low-moderate strength antibodies as identified on the Immucor platform. Within this context, it is also important for clinicians and HLA laboratories to discuss how the test result would change clinical management, considering the additional turnaround-time and cost of the test, and the general lack of effective treatment for AMR. 30, 31 One rationale for testing may be to inform the selection of patients to undergo treatment with complement inhibitors. Given the current cost-prohibitive nature of these therapies, however, the C3d test may be best reserved for patients enrolled in clinical trials until access to these medications becomes more prevalent.
Results of this study should be interpreted in view of certain limitations. First, as with all retrospective studies, our analysis is subject to unknown confounders between the 2 groups. One example is differences in the selection criteria for patients to receive AMR treatment and the drug regimens used by different centers, which were not captured in this study. Despite this limitation, there was no convincing evidence in literature during the study period that demonstrated the superiority of any AMR treatment protocol relative to others. Second, on first sight it may appear that the study underrepresented patients with low-level DSA as all subjects were required to screen positive for DSA with sum MFI > 5000 on the OL SAB platform before testing using Immucor products. Due to differences in assay protocol and sensitivity, a large proportion of our study patients in fact had MFI values < 5000 on the Immucor platform ( Figure 2) ; moreover, 3 patients that screened positive using OL SAB had to be excluded from analysis as they showed no detectable DSA on Immucor SAB. Third, we acknowledge that C3d is only one of several available assays (C4d, C1q, IgG subclass) that can interrogate the complement activity of antibodies. Without performing these tests in parallel our results are not directly applicable to information derived from other assays. Similarly, given key differences between antibody detection platforms, conclusions regarding C3d and its utility should be limited to laboratories that use Immucor reagents. Fourth, given the general unavailability of HLA typing for DPA/B loci, potential DSA against DP antigens could not be determined, although we note that only a minority (5/106, 4.7%) of patients tested positive for anti-DP antibodies. Finally, as our dataset lacks patient-specific clinical data (ie, nonadherence) that have been shown by others 15 to be prognostically important, the additional benefit of C3d relative to certain clinical predictors remains undefined.
In summary, C3d positivity in kidney recipients presenting with late dysfunction was associated with a worse renal outcome and faster progression to graft loss compared to patients with C3d-DSA. Despite the prognostic value of C3d as a stand-alone test, the assay did not provide independent risk prediction after integration of graft fibrosis into the model. For laboratories that run the Immucor assay, the C3d test adds marginal risk stratification for strong antibodies with peak IgG MFI > 10 000 and in patients where histology is available, but its utilization may be considered in those with low-moderate level DSA and where an allograft biopsy is not accessible.
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